Millennium Management’s Myriad Genetics MYGN Stock Holding History

Millennium Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-75,400	Closed	-$1.84M	–	6342
2024 Q2	$1.84M	Buy	+75,400	New	+$1.65M	﹤0.01%	3598
2024 Q1	–	Sell	-30,000	Closed	-$574K	–	6481
2023 Q4	$574K	Buy	+30,000	New	+$519K	﹤0.01%	4559
2021 Q3	–	Sell	-10,000	Closed	-$306K	–	7083
2021 Q2	$306K	Sell	10,000 -10,000	-50%	-$289K	﹤0.01%	5706
2021 Q1	$609K	Buy	+20,000	New	+$568K	﹤0.01%	4664
2019 Q3	–	Sell	-111,600	Closed	-$3.1M	–	4421
2019 Q2	$3.1M	Sell	111,600 -98,400	-47%	-$2.78M	﹤0.01%	2129
2019 Q1	$6.97M	Buy	+210,000	New	+$6.39M	0.01%	1533
2017 Q4	–	Sell	-170,000	Closed	-$6.15M	–	3978
2017 Q3	$6.15M	Buy	+170,000	New	+$4.85M	0.01%	1548
2014 Q4	–	Sell	-50,000	Closed	-$1.93M	–	4158
2014 Q3	$1.93M	Buy	+50,000	New	+$1.87M	﹤0.01%	1889
2014 Q2	–	Sell	-38,400	Closed	-$1.31M	–	3707
2014 Q1	$1.31M	Sell	38,400 -261,600	-87%	-$8.1M	﹤0.01%	2064
2013 Q4	$6.29M	Buy	300,000 +245,300	+448%	+$6.2M	0.02%	991
2013 Q3	$1.28M	Buy	+54,700	New	+$1.55M	﹤0.01%	1948

Other funds holding MYGN

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management's MYGN Position: Q1 2026 in Review

Millennium Management reduced its Myriad Genetics (MYGN) stake by 0.47% in Q1 2026, selling an estimated $163K and leaving 6,668,817 shares worth $30M. The position accounts for 0.01% of the portfolio, ranked #1228.

Millennium Management first reported a position in MYGN in Q2 2013 and has held it in 46 quarters since. The position peaked at $142M in Q3 2024. 202 funds tracked by Wall St. Rank hold MYGN as of Q1 2026.

Millennium Management held 6,668,817 shares of Myriad Genetics worth $30M as of Q1 2026.
Millennium Management sold 31,341 Myriad Genetics shares in Q1 2026, an estimated $163K.
Myriad Genetics made up 0.01% of Millennium Management's portfolio in Q1 2026, its #1228 holding.
Millennium Management first reported a position in Myriad Genetics in Q2 2013 and has held it in 46 quarters since.
Millennium Management's Myriad Genetics position peaked at $142M in Q3 2024.
202 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.